Abstract 445P
Background
Trastuzumab emtansine (T-DM1) is recommended as the standard treatment of second-line therapy of HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. However, subsequent therapeutics after T-DM1 failure remain controversial. This study investigated the effectiveness and safety of tyrosine kinase inhibitors (TKIs)-based therapy in HER2-positive MBC with T-DM1 resistance.
Methods
From September 2018 to October 2021, 53 patients with HER2-positive MBC who received TKIs-based therapy after T-DM1 failure were enrolled in this multicenter real-world study. The primary endpoint was progression free survival (PFS). Secondary endpoints included objective response rate (ORR), overall survival (OS), clinical benefit rate (CBR) and safety.
Results
53 patients received TKIs-based therapy in 2 or later line treatment. The median PFS of TKIs-based therapy was 11.9 months (95% CI 7.9-15.9). ORR and CBR were 19.6% and 72.5%, respectively. A median PFS of 10.5 months (95% CI 7.5-13.5) and an intracranial ORR of 33.3% were observed among patients with brain metastasis (n=12). A better PFS was observed among patients with pyrotinib (n=21) compared with lapatinib (n=30), and patients who derived favorable benefit from T-DM1 (PFS ≥ 6 months). Hormone receptor status (HR) and T-DM1 response were independent indicators for curative effect of TKIs-based therapy. The most commonly adverse events were thrombocytopenia (23.6%), diarrhea (15.7%), leucopenia (15.7%), and hand-foot syndrome (15.7%).
Conclusions
TKIs-based therapy showed promising efficacy and safety in patients with HER2-positive MBC after T-DM1 failure, including those with brain metastases. Patients who benefited from prior T-DM1 achieved a significantly longer PFS in subsequent TKIs-based therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Province Hospital.
Funding
Y. Yin.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
423P - A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
Presenter: Huang wei
Session: Poster session 03
424P - Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
Presenter: Xichun Hu
Session: Poster session 03
425P - Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
Presenter: Blanca Tavara
Session: Poster session 03
427P - Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
Presenter: biyun Wang
Session: Poster session 03
428P - Palbociclib dose patterns in Swedish patients with metastatic breast cancer: 5-year update from the SIRI study
Presenter: Antonis Valachis
Session: Poster session 03
429P - The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study
Presenter: Hasan Yildirim
Session: Poster session 03
430P - Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries
Presenter: Carmen Criscitiello
Session: Poster session 03
431P - Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2- metastatic breast cancer (MBC) patients (pts)
Presenter: Eleonora Nicolo
Session: Poster session 03
432P - Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor
Presenter: Lucia Navarro Berlanga
Session: Poster session 03